Ying Zhou

发表

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

T. Miyamoto, C. Dinardo, N. Komatsu, 2021, Japanese journal of clinical oncology.

Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer

N. Jin, Yanqiu Fang, Ying Zhou, 2022, Journal of oncology.

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

A. Letai, B. Leber, J. Esteve, 2020, The New England journal of medicine.

Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial

Yong Gao, Yandong Li, Yanan Hai, 2020, Journal of Cancer Research and Clinical Oncology.

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Wan-Jen Hong, G. Garcia-Manero, Jacqueline S. Garcia, 2019, Blood.

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Wan-Jen Hong, K. Götze, G. Garcia-Manero, 2019, Blood.

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Wan-Jen Hong, G. Garcia-Manero, Jacqueline S. Garcia, 2020 .

AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A

J. Esteve, H. Döhner, Wan-Jen Hong, 2020 .

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

H. Döhner, C. Dinardo, Jacqueline S. Garcia, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma

Ying Zhou, Xiaohong Xu, 2022, Hematology.

Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

G. Garcia-Manero, Jacqueline S. Garcia, U. Borate, 2021, Blood.

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

M. Loh, T. Farazi, C. Zwaan, 2018, Future oncology.

Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.

K. Götze, G. Garcia-Manero, Jacqueline S. Garcia, 2018 .

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

C. Dinardo, Jacqueline S. Garcia, Jianxiang Wang, 2022, Blood.

Autoimmune thrombocytopenia: a complication of fludarabine therapy in the treatment of Waldenstrom's macroglobulinemia.

Dai Yuan, X. Sui, Hongzhi Xu, 2014, International journal of clinical and experimental medicine.

Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.

H. Döhner, C. Dinardo, Jacqueline S. Garcia, 2021 .

A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival.

G. Garcia-Manero, Jacqueline S. Garcia, D. Steensma, 2021, Leukemia research.

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

G. Garcia-Manero, Jacqueline S. Garcia, U. Borate, 2022, American journal of hematology.

Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes.

G. Garcia-Manero, Jacqueline S. Garcia, P. Fenaux, 2021 .

The Circular RNA Circ-ANAPC7 as a Biomarker for the Risk Stratification of Myelodysplastic Syndrome

Ying Qu, Shuying Zhang, Ying Zhou, 2022, Indian Journal of Hematology and Blood Transfusion.

Safety and Efficacy of the BCL Inhibitors Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: ALL‐131

C. Mullighan, E. Jabbour, J. Rubnitz, 2018, Clinical Lymphoma Myeloma and Leukemia.

Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia

C. Dinardo, K. Porkka, K. Pratz, 2024, American journal of hematology.